• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Member Resources

Pipelines in Oncology

November 19, 2009 - BristolMyersSquibb

http://www.bms.com

Rob Kramer - Vice President of Discovery Biology
Steve Auerbach - Vice President of Research and Development

Presentations on:

  • Ixempra
  • Sprycel
  • Erbitux
  • Ipilimumab
  • Tanespimycin
  • XL-184
  • IGF-R Antagonist
  • VEGF R-2 Adnectin
  • Inhibitor (CT-322)
  • ErbB/VEGF Inhibitor
  • Anti-CD 137 antibody
  • Epothilone-Folate
  • SMO Inhibitor
  • Cdc7 Inhibitor (XL-413)
  • Anti-CS1 antibody (Elotuzumab)
  • Adnectin Bispecific Inhibitor
  • RAF Kinase Inhibitor (XL-281)


November 5, 2009 - Abraxis Biosciences

http://www.abraxisbio.com

Jose Iglesis, MD - Vice President for Global Clinical Development
David Brooks, MD, PhD - Medical Director for Global Clinical Development
Kathy Meyer - Medical Liaision

Presentations on:

  • Nab-paclitaxel
  • ABI-008 (Nab-docetaxel)
  • ABI-009 (Nab-rapamycin)
  • ABI-010 (Nab-17AAG-Hsp90 inhibition)
  • ABI-011 (Nab-dual mechanism inhibitor)
  • ABI-0013 (Nab - novel taxane)


October 22, 2009 - Momenta Pharmaceuticals

http://www.momentapharma.com

Kei Kishimoto, PhD

Presentations on:

  • M402 - novel heparin sulfate proteoglycan


September 17, 2009 - Novartis

http://www.novartis.com

William Sellers, PhD - Vice President, Global Head Oncology
Barbara Weber, MD - Senior Vice President of Translational Medicine

Presentations on:

  • Therapeutic Targeting of Oncogenic Pathways


June 9, 2009 - Avila Therapeutics

http://www.avilatx.com

Erica Evans, PhD - Senior Scientist
Mariana Nacht, PhD - Director, Molecular and Cell Biology
William Westlin, PhD - Vice President, Preclinical Research

Presentation on:

  • AVL291- btk inhibitor (B-cell malignancies)
  • panErB inhibitor program
  • PI3K inihbitor program


May 21, 2009 - Amgen

http://www.amgen.com

Sean Harper, MD - Senior Vice President Global Development and Chief Medical Officer
David Chang, MD, PhD - Vice President Global Development TA Head Hematology/Oncology 
John Newcomb, PhD-  Director Oncology Research
Douglas Saffran, PhD Principal Scientist, Oncology Research

Presentation on:

  • Overview over Amgen pipeline, with focus on Angiopoietin-Tie2 Pathway (AMG 386), HER 3, HGS/SF- c-met pathway (AMG102).


May 19, 2009 - OSI Pharmaceuticals (Biomarkers and Diagnostics Group)

http://www.osip.com

Marta Hamilton, PhD - Vice President, Preclinical Development and Pharmacology
Frank Richardson, PhD - Senior Director, Safety Assessment and Molecular Markers
Phil Rutledge, MA, MBA - Director, Medical Science Liaisons

Presentation on:

  • OSI Biomarkers and Diagnostics Efforts


April 30, 2009 - AstraZeneca

http://www.astrazeneca.com

Louise Grochow, MD Executive Director of Global Medical Science
Jeff Hanke, PhD Vice President, Cancer Research
Greg Curt, MD US Medical Science Lead, Oncology

Presentation on:

  • Overview of AstraZeneca Pipeline


February 9, 2009 - Ariad Pharmaceuticals

http://www.ariad.com

Pierre F. Dodion, M.D. - Senior Vice President and Chief Medical Officer
Frank G. Haluska, M.D., Ph.D. - Vice President, Clinical Research
Tim Clackson, Ph.D. - Senior Vice President and Chief Scientific Officer

Presentation on:

  • Deforolimus: oral mTOR inhibitor, currently in phase 3 development in sarcoma, as well as numerous phase 1 and 2 studies
  • AP24534: once-daily oral pan-Bcr-Abl inhibitor, currently in phase 1 development in heme malignancies including CML; also an inhibitor of FGFRs and other angiogenesis-related targets
  • ALK inhibitor: new program recently announced; a selective, orally active agent currently in preclinical development.


January 27, 2009 - Sanofi-Aventis

http://www.sanofi-aventis.us/live/us/en/index.jsp

Nassir Habboubi - Vice President, Head US Medical
Svetlana Kobina, MD PHD -  Associate Vice President USMA - GI and Lung
Grannum Sant, MD - Vice President US Medical -Urology
Mohamed Zaki, MD PhD - R&D US Clinical Research Unit

Presentation on:

  • Afibercept (VEGF-Trap, an anti-angiogenesis agent)
  • Two Taxane Analogs: Larotaxel and XRP6258
  • Alvocidib (Flavopiridol, a pan CDK-inhibitor)
  • AVE8062 (Vascular Disruption Agent)
  • Trovax (Therapeutic vaccine)


January 22, 2009 - Wyeth

http://www.wyeth.com

Jay Gibbons Associate Vice President Discovery
Charlie Zacharchuk - Senior Director CR&D/Early development
Anna Berkenblit - Director, Medical Monitor Neratinib program
Chris Coughlin - Director, Medical Monitor neratinib / translational medicine expert

Presentation on:

  • Wyeth Discovery Compounds/ Research Platform
  • Neratinib - Irreversible panErbB inhibitor
  • SKI 606 - Src Abl Kinase Inhibitor for Breast Cancer